Universal HLA-E mRNA vaccine platform
This technology utilises mRNA-encoded HLA-E–β2 microglobulin–peptide single-chain trimers to directly present target antigens on cell surfaces. It enables robust, HLA restricted T cell activation without reliance on conventional antigen processing pathways.
Applications: Therapeutic cancer vaccines, prophylactic and therapeutic viral vaccines
| Features | Benefits |
|---|---|
| Universal vaccine applicability | By targeting HLA-E, a non-polymorphic molecule, this platform enables consistent immune responses across all patients - eliminating the need for HLA-matched vaccine design |
| Direct antigen presentation for enhanced immunogenicity | The single-chain trimer design bypasses inefficient antigen processing pathways, ensuring stable and highlevel presentation of target peptides to T cells, improving immune activation |
| Overcomes limitations of conventional vaccines | Traditional protein or mRNA vaccines rely on intracellular antigen processing, which is inefficient for HLA-E due to low peptide binding affinity. This approach directly solves that bottleneck |
| mRNA and lipid nanoparticle compatibility | Built on clinically validated mRNA-LNP delivery systems, the platform supports rapid development, scalable manufacturing, and flexible antigen design - aligned with current vaccine infrastructure |
| Tuneable and optimisable design | The platform allows engineering of peptide sequences and HLA-E constructs (e.g. mutations to enhance stability or surface expression), enabling optimisation for potency and durability |
Available For
- Co-development
- Consulting
- Licensing